HK1211593A1 - Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease - Google Patents
Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological diseaseInfo
- Publication number
- HK1211593A1 HK1211593A1 HK15112222.8A HK15112222A HK1211593A1 HK 1211593 A1 HK1211593 A1 HK 1211593A1 HK 15112222 A HK15112222 A HK 15112222A HK 1211593 A1 HK1211593 A1 HK 1211593A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diagnostic
- treatment
- human antibodies
- therapeutic uses
- neurological disease
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45536310P | 2010-10-19 | 2010-10-19 | |
US201161537392P | 2011-09-21 | 2011-09-21 | |
US201161546634P | 2011-10-13 | 2011-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1211593A1 true HK1211593A1 (en) | 2016-05-27 |
Family
ID=45975788
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15112222.8A HK1211593A1 (en) | 2010-10-19 | 2015-12-11 | Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease |
HK19100399.6A HK1258028A1 (zh) | 2010-10-19 | 2019-01-10 | 人類抗體及其在神經疾病治療中的診斷和治療用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK19100399.6A HK1258028A1 (zh) | 2010-10-19 | 2019-01-10 | 人類抗體及其在神經疾病治療中的診斷和治療用途 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20130280167A1 (ja) |
EP (2) | EP2629795B1 (ja) |
JP (5) | JP6000959B2 (ja) |
CN (2) | CN104725507B (ja) |
AU (2) | AU2011318567B2 (ja) |
BR (1) | BR112013009673B1 (ja) |
CA (2) | CA3037903A1 (ja) |
ES (1) | ES2662100T3 (ja) |
HK (2) | HK1211593A1 (ja) |
IL (2) | IL225837B (ja) |
NZ (2) | NZ624752A (ja) |
WO (1) | WO2012054077A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011318567B2 (en) * | 2010-10-19 | 2017-02-09 | Mayo Foundation For Medical Education And Research | Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease |
NZ701278A (en) * | 2012-04-17 | 2016-12-23 | Mayo Foundation | Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions |
BR112016018313A8 (pt) | 2014-02-10 | 2018-06-12 | Igm Biosciences Inc | Moléculas de ligação multiespecíficas iga |
KR102380402B1 (ko) | 2014-04-03 | 2022-03-31 | 아이쥐엠 바이오사이언스 인코포레이티드 | 변형된 j-사슬 |
US11180543B2 (en) * | 2014-11-07 | 2021-11-23 | Mayo Foundation For Medical Education And Research | Treatment of neonatal hypoxia including impairments or effects thereof |
IL297997A (en) | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | CD20 binding compounds and their uses |
DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
EP3355913A1 (en) | 2015-09-30 | 2018-08-08 | IGM Biosciences A/S | Binding molecules with modified j-chain |
CN112037147B (zh) * | 2020-09-02 | 2024-05-14 | 上海联影医疗科技股份有限公司 | 医学图像降噪方法和装置 |
EP4251202A1 (en) * | 2020-11-30 | 2023-10-04 | Merck Sharp & Dohme LLC | Arginase 1 binders for inhibiting arginase 1 activity |
CN117679488B (zh) * | 2023-12-13 | 2024-07-05 | 暨南大学附属第一医院(广州华侨医院) | 纳米拮抗剂Au-ADH1在制备治疗脊髓损伤修复药物的用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
US7473423B2 (en) * | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
DE69841894D1 (de) * | 1997-11-21 | 2010-10-21 | Merck Serono Biodevelopment Sa | Äusseres Membranpolypeptid von Chlamydia pneumoniae sowie Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion |
AU2000261978B2 (en) | 2000-05-10 | 2006-07-06 | Mayo Foundation For Medical Education And Research | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
AU2004247021A1 (en) * | 2003-05-16 | 2004-12-23 | Acorda Therapeutics | Compositions and methods including a recombinant human MAB that promotes CNS remyelination |
CA2572098C (en) * | 2004-06-30 | 2015-01-27 | Mayo Foundation For Medical Education And Research | B7-dc binding antibody |
US20060099203A1 (en) * | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
US7645575B2 (en) * | 2004-09-08 | 2010-01-12 | Xdx, Inc. | Genes useful for diagnosing and monitoring inflammation related disorders |
DE602005027258D1 (de) * | 2005-03-14 | 2011-05-12 | Us Gov Health & Human Serv | Humane monoklonale antikörper gegen hendra- und nipah-viren |
RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
US8728477B2 (en) * | 2007-09-19 | 2014-05-20 | Immune Pharmaceuticals Ltd. | Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof |
US10202430B2 (en) * | 2007-10-18 | 2019-02-12 | Mayo Foundation For Medical Education And Research | IgM-mediated receptor clustering and cell modulation |
AU2009221916A1 (en) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
KR101671886B1 (ko) * | 2008-06-25 | 2016-11-04 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Vegf를 억제하는 안정하고 가용성인 항체 |
AU2011318567B2 (en) * | 2010-10-19 | 2017-02-09 | Mayo Foundation For Medical Education And Research | Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease |
-
2011
- 2011-10-19 AU AU2011318567A patent/AU2011318567B2/en not_active Ceased
- 2011-10-19 EP EP11834753.3A patent/EP2629795B1/en active Active
- 2011-10-19 EP EP17205247.4A patent/EP3345619A1/en not_active Withdrawn
- 2011-10-19 CA CA3037903A patent/CA3037903A1/en active Pending
- 2011-10-19 JP JP2013534892A patent/JP6000959B2/ja not_active Expired - Fee Related
- 2011-10-19 CA CA2815046A patent/CA2815046C/en active Active
- 2011-10-19 CN CN201510019719.4A patent/CN104725507B/zh active Active
- 2011-10-19 US US13/880,415 patent/US20130280167A1/en not_active Abandoned
- 2011-10-19 BR BR112013009673-0A patent/BR112013009673B1/pt not_active IP Right Cessation
- 2011-10-19 CN CN201180061125.XA patent/CN103429260B/zh active Active
- 2011-10-19 ES ES11834753.3T patent/ES2662100T3/es active Active
- 2011-10-19 NZ NZ624752A patent/NZ624752A/en unknown
- 2011-10-19 NZ NZ609607A patent/NZ609607A/en unknown
- 2011-10-19 WO PCT/US2011/001773 patent/WO2012054077A2/en active Application Filing
-
2013
- 2013-04-18 IL IL225837A patent/IL225837B/en active IP Right Grant
-
2015
- 2015-12-11 HK HK15112222.8A patent/HK1211593A1/xx not_active IP Right Cessation
-
2016
- 2016-04-08 JP JP2016077993A patent/JP2016130259A/ja not_active Withdrawn
-
2017
- 2017-05-03 AU AU2017202957A patent/AU2017202957B2/en not_active Ceased
-
2018
- 2018-03-19 JP JP2018051084A patent/JP6768728B2/ja not_active Expired - Fee Related
- 2018-09-13 IL IL261742A patent/IL261742B/en active IP Right Grant
-
2019
- 2019-01-10 HK HK19100399.6A patent/HK1258028A1/zh unknown
-
2020
- 2020-05-07 US US16/869,344 patent/US20200397898A1/en not_active Abandoned
- 2020-05-22 JP JP2020089544A patent/JP2020141696A/ja not_active Withdrawn
-
2022
- 2022-04-04 JP JP2022062441A patent/JP2022091948A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1258028A1 (zh) | 人類抗體及其在神經疾病治療中的診斷和治療用途 | |
HK1163500A1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
HUS2400027I1 (hu) | Rekombináns humán G-CSF dimer és alkalmazása, neurológiai betegségek kezelésében | |
PT2642962T (pt) | Aparelho de massagem do corpo humano ou animal | |
HK1169455A1 (zh) | 阿爾茨海默病的診斷和治療 | |
HK1215787A1 (zh) | 用於治療疼痛的藥物組合 | |
EP3628326C0 (en) | METHODS AND SUBSTANCES FOR TREATING PUMP DISEASE | |
IL260078B (en) | Therapy used to treat Gaucher disease | |
GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
EP2563395A4 (en) | TREATMENT WITH ANTI-S1P ANTIBODY OF PATIENTS WITH OCULAR DISEASES | |
EP2624821A4 (en) | POLYTHERAPY FOR THE TREATMENT OF DEPRESSION AND OTHER NON-INFECTIOUS DISEASES | |
EP2707486A4 (en) | DIAGNOSIS AND TREATMENT OF FRIEDREICH ATAXIA | |
IL213703A (en) | Compounds for the treatment of pain and other diseases | |
EP2454372A4 (en) | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS | |
EP2569334A4 (en) | RECOMBINANT-PRODUCED ANTIBODIES FOR THE TARGETING OF ERBB SIGNALING MOLECULES AND METHOD FOR THEIR USE FOR DISEASE DIAGNOSIS AND TREATMENT | |
EP2470268A4 (en) | PURING-ORIENTED DIAGNOSIS AND THERAPY OF WOUNDS | |
GB0914423D0 (en) | Treatment of protein aggregation diseases | |
HK1203190A1 (en) | Compounds for use in imaging, diagnosing and or treatment of diseases of the central nervous system | |
EP2361317A4 (en) | USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
IL217133A0 (en) | Diagnosis and treatment of autoimmune demyelinating diseases | |
HU0900195D0 (en) | Diagnosis and treatment of gluten-induced autoimmune diseases | |
EP2588866A4 (en) | DIAGNOSIS AND TREATMENT OF BRAIN TUMORS | |
DK2665746T3 (en) | Antibodies against the s100p protein for the treatment and diagnosis of cancer | |
ZA201306759B (en) | Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system | |
GB201018362D0 (en) | Treatment of dupuytren's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20231023 |